S-1 and CPT-11 plus ramucirumab (IRIS1Rmab) as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: A multicenter phase II study in Japan (N-DOCC-F-C-1701)

被引：0
|
作者：
Kobayashi, K. [1 ]
Morita, M. [1 ]
Ito, S. [1 ]
Inoue, Y. [1 ]
Yamaguchi, I. [1 ]
Kosaka, T. [1 ]
Kuba, S. [1 ]
Sakimura, C. [1 ]
Soyama, A. [1 ]
Adachi, T. [1 ]
Ohno, S. [1 ]
Kobayashi, S. [1 ]
Hara, T. [1 ]
Hidaka, M. [1 ]
Hayashida, N. [1 ]
Yamanouchi, K. [1 ]
Kanetaka, K. [1 ]
Takatsuki, M. [1 ]
Eguchi, S. [1 ]
机构：
[1] Nagasaki Univ, Grad Sch Biomed Sci, Dept Surg, Nagasaki, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
192TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer
    Kim, Sun Young
    Hong, Yong Sang
    Kim, Byung Chang
    Park, Ji Won
    Choi, Hyo Seong
    Jeong, Seung-Yong
    Kim, Dae Yong
    Hong, Chang Won
    Sohn, Dae Kyung
    Jung, Kyung Hae
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (03) : 269 - 274
  • [32] A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer
    Sun Young Kim
    Yong Sang Hong
    Byung Chang Kim
    Ji Won Park
    Hyo Seong Choi
    Seung-Yong Jeong
    Dae Yong Kim
    Chang Won Hong
    Dae Kyung Sohn
    Kyung Hae Jung
    Investigational New Drugs, 2009, 27 : 269 - 274
  • [33] A multicenter phase II study of S-1 plus ramucirumab as first-line treatment in elderly patients with advanced/recurrent gastric cancer (KSCC1701).
    Katsuya, Hiroo
    Suyama, Koichi
    Kobayashi, Kazuma
    Izawa, Naoki
    Uenosono, Yoshikazu
    Hu, Qingjiang
    Kusumoto, Tetsuya
    Otsu, Hajime
    Orita, Hiroyuki
    Kawanaka, Hirofumi
    Shibao, Kazunori
    Koga, Satoshi
    Shimokawa, Mototsugu
    Makiyama, Akitaka
    Saeki, Hiroshi
    Oki, Eiji
    Baba, Hideo
    Mori, Masaki
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients
    Kim, Hyun Jung
    Yun, Jina
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Lee, Tae Hoon
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Nam Su
    Moon, Jong Ho
    Park, Sang Heum
    Lee, Kyu Taek
    Park, Seong Kyu
    Won, Jong-Ho
    Park, Hee Sook
    Hong, Dae Sik
    ONCOLOGY LETTERS, 2012, 3 (06) : 1314 - 1318
  • [35] Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study
    Park, Se Hoon
    Kim, Young Saing
    Hong, Junshik
    Park, Jinny
    Nam, Eunmi
    Cho, Eun Kyung
    Shin, Dong Bok
    Lee, Jae Hoon
    Lee, Woon Kee
    Chung, Min
    ANTI-CANCER DRUGS, 2008, 19 (03) : 303 - 307
  • [36] Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan
    Ziras, N.
    Potamianou, A.
    Varthalitis, I.
    Syrigos, K.
    Tsousis, S.
    Boukovinas, I.
    Tselepatiotis, E.
    Christofillakis, C.
    Georgoulias, V.
    ONCOLOGY, 2006, 70 (02) : 106 - 114
  • [37] Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer
    Hitoshi Kusaba
    Taito Esaki
    Junji Kishimoto
    Keita Uchino
    Shuji Arita
    Hozumi Kumagai
    Kenji Mitsugi
    Koichi Akashi
    Eishi Baba
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 29 - 34
  • [38] Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer
    Kusaba, Hitoshi
    Esaki, Taito
    Kishimoto, Junji
    Uchino, Keita
    Arita, Shuji
    Kumagai, Hozumi
    Mitsugi, Kenji
    Akashi, Koichi
    Baba, Eishi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 29 - 34
  • [39] A phase II trial of panitumumab with irinotecan and S-1 (IRIS) as second-line treatment in patients with wild-type KRAS metastatic colorectal cancer.
    Shimoyama, Rai
    Kimura, Tetsuo
    Takaoka, Toshi
    Sakamoto, Kazuki
    Kawamoto, Shunji
    Yoshizaki, Koji
    Negoro, Yuji
    Goda, Fuminori
    Tsuji, Akihito
    Nakayama, Tsuyoshi
    Miyamoto, Hiroshi
    Takayama, Tetsuji
    Niitsu, Yoshiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [40] S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis
    S Y Kim
    Y S Hong
    E K Shim
    S-Y Kong
    A Shin
    J Y Baek
    K H Jung
    British Journal of Cancer, 2013, 109 : 1420 - 1427
12345